The Role of High-Dose Chemotherapy and Stem-Cell Transplantation in Patients with Multiple Myeloma: A Practice Guideline of the Cancer Care Ontario Practice Guidelines Initiative
- 16 April 2002
- journal article
- guideline
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 136 (8) , 619-629
- https://doi.org/10.7326/0003-4819-136-8-200204160-00012
Abstract
The Hematology Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative has systematically reviewed the published literature and, through a consensus process, developed an evidence-based practice guideline assessing the role of stem-cell transplantation in patients with multiple myeloma. The conclusions were validated by solicited feedback from 221 practitioners across Ontario, Canada. The guideline comprises six recommendations: 1) Autologous transplantation is recommended for patients with stage II or III myeloma and good performance status. Evidence of benefit is strongest for patients who are younger than 55 years of age and have a serum creatinine level less than 150 µmol/L [<1.7 mg/dL]. Physicians must use clinical judgment in recommending transplantation to other patients. 2) Allogeneic transplantation is not recommended as routine therapy. 3) Patients potentially eligible for transplantation should be referred for assessment early after diagnosis and should not be extensively exposed to alkylating agents before collection of stem cells. 4) Autologous peripheral blood stem cells should be harvested early in the patient's treatment course. The best available data suggest that transplantation is most advantageous when performed as part of initial therapy. 5) The comparative data addressing the specifics of the transplantation process are insufficient to allow definitive recommendations. In the absence of such data, a single transplant with high-dose melphalan, with or without total-body irradiation, is suggested for patients undergoing transplantation outside a clinical trial. 6) At this time, no conclusions can be reached about the role of interferon therapy after transplantation. *For members of the Hematology Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative, see Appendix.Keywords
This publication has 28 references indexed in Scilit:
- Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation.Oncology Reports, 1998
- A randomized trial of maintenance interferon following high‐dose chemotherapy in multiple myeloma: long‐term follow‐up resultsBritish Journal of Haematology, 1998
- Faster engraftment but no reduction in infectious complications after peripheral blood stem cell transplantation compared to autologous bone marrow transplantation.Supportive Care in Cancer, 1998
- Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myelomaBritish Journal of Cancer, 1997
- Peripheral Blood Stem Cell and Bone Marrow Transplantation for Solid Tumors and Lymphomas: Hematologic Recovery and Costs: A Randomized, Controlled TrialAnnals of Internal Medicine, 1997
- Autologous and allogeneic transplantation for multiple myeloma at a single centreBone Marrow Transplantation, 1997
- Comparison of Interferon Tolerance after Autologous Bone Marrow or Peripheral Blood Stem Cell Transplants for Myeloma Patients who have Responded to Induction TherapyLeukemia & Lymphoma, 1996
- The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation.Journal of Clinical Oncology, 1995
- Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials.Journal of Clinical Oncology, 1992
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975